Skip to Main Content

PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of muscle function in patients in a randomized clinical trial designed to keep the drug on the market in Europe.

But a separate analysis of the same study data that might allow PTC to seek approval in the U.S. failed to reach statistical significance.


Shares of PTC rose 18% to $33 in early Tuesday trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.